|drug3223||Standard of Care (SOC) Wiki||0.45|
There is one clinical trial.
Systemic medical ozone has proved to help in several viral diseases, chronic obstructive pulmonary disease and chronic inflammation process. The investigators are sure that its application to COVID-19 patients, as an adjuvant therapy, will improve the health status of these individuals.
Description: World Health Organization (WHO) recommended COVID19 clinical scaleMeasure: COVID19 clinical scale Time: through study completion, an average of 3 weeks
Description: Dead patients during the trialMeasure: Number of died patients Time: through study completion, an average of 3 weeks
Description: Oro/nasopharynx virusMeasure: Oro/nasopharynx virus Time: through study completion, an average of 3 weeks
Description: Thorax imaging according scale. Higher punctuation is worse.Measure: Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation) Time: through study completion, an average of 3 weeks
Description: Days in hospitalMeasure: Days in hospital Time: through study completion, an average of 3 weeks
Description: Venous gas blood analysisMeasure: Venous gas blood analysis Time: through study completion, an average of 3 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports